Share Name Share Symbol Market Type Share ISIN Share Description
Aptamer Group Plc LSE:APTA London Ordinary Share GB00BNRRP542 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.50 -6.02% 39.00 18,783 16:17:07
Bid Price Offer Price High Price Low Price Open Price
38.00 40.00 41.50 39.00 41.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 27
Last Trade Time Trade Type Trade Size Trade Price Currency
16:17:03 O 16,000 37.00 GBX

Aptamer (APTA) Latest News

More Aptamer News
Aptamer Investors    Aptamer Takeover Rumours

Aptamer (APTA) Discussions and Chat

Aptamer Forums and Chat

Date Time Title Posts
24/1/202311:35☆☆ Aptamer Group - Novel Antibody Mimetics (Optimers) ☆☆39

Add a New Thread

Aptamer (APTA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-02-03 16:17:0537.0016,0005,920.00O
2023-02-03 16:01:4841.00124.92O
View all Aptamer trades in real-time

Aptamer (APTA) Top Chat Posts

Top Posts
Posted at 04/2/2023 08:20 by Aptamer Daily Update
Aptamer Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker APTA. The last closing price for Aptamer was 41.50p.
Aptamer Group Plc has a 4 week average price of 38.50p and a 12 week average price of 38.50p.
The 1 year high share price is 132.50p while the 1 year low share price is currently 38.50p.
There are currently 69,012,594 shares in issue and the average daily traded volume is 2,532 shares. The market capitalisation of Aptamer Group Plc is £26,914,911.66.
Posted at 23/12/2022 12:42 by sharesoc
In case you missed our webinar with Aptamer Group (APTA), the recording can be found on our YouTube channel: hTTps://
Posted at 18/11/2022 21:42 by sharesoc
ShareSoc is hosting a webinar with Aptamer Group (APTA) on 06 December 2022, which may be of interest to current shareholders or potential investors. Dr Arron Tolley (CEO)
and Jenny Cutler (Interim CFO) will be presenting.

You can register here: hTTps://

Posted at 19/10/2022 05:57 by timbo003
Broker comment following yesterday's results:

Aptamer has published FY’22 (June Y/E) results that are in line with our expectations and the investment thesis set out at IPO. FY’23 has started well with multiple repeat and new contracts signed post period-end, and management are on track to meet our expectations for further fee-for-service revenue growth in FY’23. The Group remains wellcapitalised with funding to EBITDA breakeven in 2024. This gives ample runway to focus on continuing to build its pipeline of blue-chip customers and capitalising on the high interest it is seeing for its aptamer discovery selection services across all three life science divisions. We have left forecasts broadly unchanged, but as management continues to deliver on fee-for-service revenue growth it fuels licensing discussions to target converting that could drive outperformance. Our DCF-derived target price is unchanged at £2.70, and we maintain our Buy rating.

Posted at 22/8/2022 09:38 by elpirata
Unlike most biotech IPO's which tend to be R&D stage APTA has already commercialised its Optimers & has ratcheting material contract income
H2 2020 £485,000
H1 2021 £1,373,000
H2 2021 circa £2,600,000 (interpolated from £4m full year)
Gross profit margin of 58% from H1 is decent
Full year admin interpolated from H1 should be circa £3m?
H1 cashburn £3.1m & has £6.7m cash so should be funded for a year reflecting stated move to larger labs & recruitment

59,739,600 shares in issue tightly held, management & principal IPO funders are locked in from IPO to Jan 2023, free float only 8.75m

In aggregate, therefore, at Admission, 85.34 per cent. of the Enlarged Ordinary Share Capital will be subject to lock-in and orderly market arrangements.

Posted at 22/8/2022 06:51 by timbo003
Liberum comment on this morning's update:

"In its maiden full-year trading statement, Aptamer has delivered approx. 150% revenue growth, meeting our expectations set at IPO. Momentum is building, and while there was an outperformance on cash, funds continue to be deployed to capitalise on the growing development pipeline and to accelerate revenues further. All existing collaborations continue to progress including potentially material projects with major pharma and life science tool companies that could significantly further improve the company’s prospects. We reiterate our BUY with our DCFderived target price of 270p unchanged and pointing to over 180% upside."

I suspect the market will act favourably to this update, maybe back to just over £1?

Posted at 24/2/2022 06:52 by timbo003
Liberum have issued an initiation note this morning

The affinity ligand market is large (~$145bn) and growing at
double digits. It is dominated by antibody technology, but
they aren’t perfect, falling short of requirements 50% of the
time. Aptamer has developed an alternate affinity ligand
technology that has proven effective in 70% of projects
where antibodies have failed. Aptamer’s fee-for-service
model is gaining traction with healthcare partners across a
range of applications, and the BD pipeline has grown
accordingly. Our DCF model values Aptamer at £185m, or
£2.70 per share, 105% upside. We initiate with a BUY.

Posted at 24/1/2022 10:54 by amanitaangelicus
Still holding small amount. No interest in the stock. Will take time. Sell price set from the outset.
Posted at 17/1/2022 13:51 by elpirata
Yes, already contracted with big pharma & should see revenue increases compounding year on year.

But its the wrong price for me to buy in at this level, £98m mcap for a company that reported a £2.9m loss on £1.6m revenues for the 15 month period to 30/6/21 is too hot imo. They need £3m pa just to cover staff & director costs.

Keeping it on monitor.

Aptamer share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230204 15:33:32